Wechselwirkungen · NovoSeven
NovoSeven 1 mg (50 KIU) powder and solvent for solution for injection NovoSeven 2 mg (100 KIU) powder and solvent for solution for injection NovoSeven 5 mg (250 KIU) powder and solvent for solution for injection NovoSeven 8 mg (400 KIU) powder and solvent for solution for injection · Abschnitt 4.5 · PDF-Seite 6
HOS-085094 · Präparat HOS-083079
Antifibrinolytics have been reported to reduce blood loss in association with surgery in haemophilia patients, especially in orthopaedic surgery and surgery in regions rich in fibrinolytic activity, such as the oral cavity. Antifibrinolytics are also used to reduce blood loss in women with postpartum haemorrhage. Experience with concomitant administration of antifibrinolytics and rFVIIa treatment is, however, limited.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-01-05T10:11:00Z · SHA-256 4cde9b1f299068eba5f867a596fb73966c9f4132d6fc783820f32def35917cf3 · Passage a9f87013d510819d16070909d3b1de54a744ac9e235cc8f023d8bf85fb9c2da4 · Zeichen 194–615 im Abschnitt